Anti-PD-1 therapy
<p>Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable <em>KRAS</em>-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review</p>
... from 1 to 36 ...by PD-1 inhibitor, sintilimab, due to positive staining of PD-L1, and achieved an overall survival of 52 ...of anti-PD-1 ...by PD-1 ...
6
Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic
... We report a case of a urothelial cancer patient with complete response to immune checkpoint blockade who developed an apparent escape lesion. The patient’s disease tracked very closely to serum AFP levels, and the strong ...
5
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
... combination anti-PD-1/anti-CTLA-4 therapy showing a durable response despite possessing worse prognostic features (GNA11 mutation, older age at pres- entation, male gender, short ...
8
Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis
... to anti-PD-1 treatment To further explore the potential molecular mechanism of drug resistance to PD-1 blockade in oral mucosal ma- lignant transformation, the expression of the ...
12
Tumor immune profiling predicts response to anti–PD 1 therapy in human melanoma
... ligand 1 (PD-L1) and PD-1 expression in tumors by routine IHC has been used in an attempt to predict response to anti–PD-1 therapy ...to ...
7
Mitochondria Determine Response to Anti-PD-1 Therapy: An Evidence-based Hypothesis
... of PD-1 on ...of PD-1, thus, enhances the anti- tumor efficacy of ...for anti–PD-1 immunotherapy, strongly support our hypothesis (16, ...
9
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report
... modality therapy including surgery and radiation appears to have a better outcome than each modality ...the PD-1 receptor or PD-L1 ligand has recently been shown to have activity in multiple ...
5
Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment
... of PD-1, PD-L1 and PD-L2 was ana- lyzed on PBMC at various time-points after stopping nivolumab (defined as day ...of PD-L1 expression was observed on B and T cells at d56 with a peak ...
5
T cell Bim levels reflect responses to anti–PD-1 cancer therapy
... ipilimumab therapy and on BRAF inhibition therapy if BRAF mutant, age over 18 years, Eastern Cooperative Oncology Group performance status of 0 to 2, adequate organ function, and life expectancy ≥3 ...
15
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
... therapeutic PD-1 antibody-bound subset, (2) upregulation of TIM-3 was only detected in tumour-bearing lungs but not in sentinel lymph nodes and peripheral blood, (3) TIM-3 positivity was significantly ...
10
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy
... to anti–PD-1 therapy is well documented (4, 14), the lack of association with reduced peCTLs suggests that other immune cells such as NK cells (27) or tumor macrophages (28) may be involved in ...
9
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
... mL if the baseline level is not available. Hepatitis was categorized into HBV-related hepatitis, cytotoxic drug- related hepatitis, hepatitis attributed to hepatic lesion progression, and immune-related hepatitis, ...
10
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
... The primary endpoint in our study is the ORR. A higher proportion of patients achieved an objective response in co- hort B (68.2% vs. 54.5%); however, the difference was not significant (P = 0.31). Similarly, the ...
10
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
... Because PD-Ligand-1 (PD-L1) expression in other tumor types has been associated with response to anti-PD-1, we investigated the expression of PD-L1 and its association ...
5
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
... increased PD-L1 expression and greater influx of Tregs was observed, likely leading to a dampened antitumor immune response gener- ated by MG1 ...inhibition therapy (consisting of ...
13
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis
... the anti-programmed cell death-1 monoclonal antibody (anti-PD-1 mAb) nivolumab, followed by combined nivolumab and the anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) ...
5
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018): Late-Breaking Abstracts
... on anti-PD-1 therapies with 36% (7/19) having had more than one prior line of ...grade 1 associated with injection site or procedural ...and 1 stable disease being observed per ...
13
Chimeric antigen receptors: unleashing a new age of anti-cancer therapy
... cell therapy with checkpoint inhibitors, such as anti-PD-1 (nivolumab, pidilizumab and pembroli- zumab), anti-PD-L1 (MDX-1105), and anti-CTLA-4 (ipilimumab), and have ...
6
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
... and PD-1 blockers are im- pressive durable response rates and manageable adverse events, but only a fraction of patients were seen to re- spond to monotherapy ...and PD-1 blockers was ...
12
Enhanced killing of chordoma cells by antibody-dependent cell- mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
... of PD-L1 expression in chordoma (Figure 1) suggested potential clinical benefit from PD-1/ PD-L1 pathway ...Several anti-PD-L1 antibodies have been generated and are being ...
14